Table 1. Hantavirus-specific antibodies in 30 HFRS patients in Estonia as determined by ELISA and FRNT*.
| Patient no. | ELISA |
FRNT of convalescent-phase serum |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Time after onset, d | PUUV IgM/IgG | SAAV IgM/IgG | Time after onset | PUUV | SAAV | DOBV | SEOV | ||
| 681 | 13 | 1.095/0.556† | 0.075/0 | 5 mo | 640‡ | 40 | <40 | <40 | |
| 715 | 12 | 1.147/0.258 | 0.052/0.045 | 21 d | 640 | <40 | <40 | <40 | |
| 716 | 17 | 1.072/0.383 | 0.028/0 | 1 mo | 2,560 | <40 | <40 | <40 | |
| 718 | 7 | 1.079/0.142 | 0/0.019 | 1 mo | 2,560 | <40 | <40 | <40 | |
| 728 | 24 | 0.602/0.727 | 0.039/0.145 | 9 mo | 640 | <40 | <40 | <40 | |
| 731 | 8 | 1.43/0.309 | 0/0.102 | 24 d | 2,560 | <40 | <40 | <40 | |
| 761 | 9 | 1.048/0.213 | 0.034/0.138 | ND | ND | ND | ND | ND | |
| 763 | 9 | 1.309/0.631 | 0.031/0.088 | ND | ND | ND | ND | ND | |
| 766 | 15 | 1.340/0.586 | 0.036/0.043 | 7 mo | 640 | <40 | <40 | <40 | |
| 767 | 16 | 1.840/0.627 | 0.040/0.034 | 12 mo | 640 | <40 | <40 | <40 | |
| 770 | 13 | 0.995/0.127 | 0.231/0.031 | 5 mo | 160 | <40 | <40 | <40 | |
| 772 | 6 | 0.331/0.044 | 0.137/0.021 | 11 mo | 160 | <40 | <40 | <40 | |
| 774 | 4 | 1.361/0.863 | 0.103/0.088 | 11 mo | 160 | <40 | 40 | <40 | |
| 800 | 8 | 1.151/0.152 | 0/0.099 | ND | ND | ND | ND | ND | |
| 812 | 9 | 1.144/0.244 | 0.026/0.046 | 9 mo | 640 | <40 | <40 | <40 | |
| 813 | 7 | 1.058/0.089 | 0.082/0.06 | 2 mo | 640 | <40 | <40 | <40 | |
| 840 | 8 | 0.724/0.038 | 0.083/0.055 | 9 mo | 640 | <40 | <40 | <40 | |
| 841 | 8 | 0.704/0.142 | 0.073/0.013 | 20 d | 2,560 | 160 | 160 | <40 | |
| 855 | 24 | 0.791/0.152 | 0.632/0.090 | 1 mo | 640 | 40 | 40 | <40 | |
| 857 | 5 | 1.133/0.043 | 1.053/0.067 | ND | ND | ND | ND | ND | |
| 861 | 23 | 1.051/0.184 | 0.559/0.035 | 1.5 mo | 640 | <40 | <40 | <40 | |
| 895 | 5 | 0.957/0.135 | ND/0.011 | 1 mo | 2,560 | <40 | <40 | <40 | |
| 899 | 13 | 0.797/0.120 | ND/0.005 | 1.5 mo | 160 | <40 | <40 | <40 | |
| 927 | 11 | 0.833/0.279 | ND/0.004 | 1.5 mo | 640 | <40 | 40 | <40 | |
| 933 | 5 | 0.569/0.464 | ND/0.116 | 18 mo | 160 | <40 | 40 | <40 | |
| 691 | 6 | 0.355/0.047 | 1.014/0.081 | 4 mo | <40 | 160 | 40 | <40 | |
| 769 | 10 | 0.271/0 | 0.218/0.254 | 20 d | <40 | 2,560 | 640 | <40 | |
| 801 | 14 | 0/0.038 | 0.394/1.548 | 1.5 mo | <40 | 640 | 160 | <40 | |
| 849 | 4 | 0.011/0 | 0.599/0.133 | ND | ND | ND | ND | ND | |
| 795 | 12 | 0.144/0 | 0.442/362 | 11 mo | <40 | 160 | 640 | <40 | |
*HFRS, hemorrhagic fever with renal syndrome; FRNT, focus reduction neutralization test; PUUV, Puumala virus; SAAV, Saaremaa virus; Ig, immunoglobulin; DOBV, Dobrava virus; SEOV, Seoul virus; ND, not done. Numbers in boldface indicated positive results in ELISA and at least 4-fold higher titer in FRNT. The cut-off value for ELISA was set at OD = 0.100. †Mean optical density (OD) for duplicate samples. ‡Reciprocal endpoint titer at an 80% reduction.